A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2004
12/16/2004	US20040254189 Jnk inhibitors
12/16/2004	US20040254186 Pyridylfurans and pyrroles as raf kinase inhibitors
12/16/2004	US20040254185 Endothelial growth factor antagonist; angiogenesis inhibitor; skin disorders; anticancer agents; endometriosis; Crohn's disease; leukemia; antiarthritic agents; vision defects
12/16/2004	US20040254177 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
12/16/2004	US20040254176 Hypotensive agents; cardiovascular disorders; antidiabetic agents; skin disorders;kidney disorders; headaches; vision defects; strokes; synergistic mixture of amlodipine, benazepril and hydrochlorothiazide; oral administering
12/16/2004	US20040254175 Antitumor agenst; thrombosis; arteriosclerosis; cardiovascular disorders; antiinflammatory agents
12/16/2004	US20040254160 Benzothiazepine derivatives
12/16/2004	US20040254157 ethyl 4-[(4-[[2-methyl-phenyl)amino]carbonyl]amino)phenyl]amino]-4-oxo-2-phenyl-butanoyl)amino]benzoate for treatment of inflammatory diseases and conditions mediated by integrins (atherosclerosis, asthma, obstructive pulmonary disease, allergies, diabetes, multiple sclerosis, and autoimmune disorders)
12/16/2004	US20040254145 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries
12/16/2004	US20040254134 Modulating heart cells; administering polynucleotide; adjust contraction
12/16/2004	US20040254128 Treatment and prevention of heat shock protein-associated diseases and conditions
12/16/2004	US20040254116 Contactor tissue with transforming growth factor kinase receptors; modulate cell proliferation
12/16/2004	US20040254107 Biphasic mixtures of glp-1 and insulin
12/16/2004	US20040254093 Antiinflammatory agents; cardiovascular disorders; anticancer agents; antidiabetic agents
12/16/2004	US20040253698 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
12/16/2004	US20040253685 eNOS mutations useful for gene therapy and therapeutic screening
12/16/2004	US20040253681 Mitogenic oxygenase regulators
12/16/2004	US20040253610 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders
12/16/2004	US20040253597 Sodium dependent dicarboxylate transport protein for use in identifying modulators for prevention/treatment of hepatic, prostate, splenic, renal diseases, metabolic, circulatory, cancer and aging disorders
12/16/2004	US20040253588 Cytochrome p450 monooxygenase for use in identifying modulators for treatment, diagnosis and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, gastrointestinal and liver disorders
12/16/2004	US20040253294 A crosslinked, acidic, high molecular weight gelatin hydrogel obtained from alkali hydrolyzed collagen, impregnated with hepatocyte growth factor, and having an isoelectric point of 5 and a zeta potential between -15 and -20 mV; angiogenesis promoters; arterial diseases
12/16/2004	US20040253276 Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization
12/16/2004	US20040253275 Pharmaceutical and cosmetic carrier or composition for topical application
12/16/2004	US20040253240 immunogens used to induce immune response against specific epitopes of apolipoproteins; prophylaxis of atherosclerosis; immunotherapy
12/16/2004	US20040253239 nucleotide sequences that code angiogenic factor antagonists and vascular endothelial structure regulators, used for prevention of angoigenesis or cancer; gene therapy
12/16/2004	US20040253231 monoclonal or polyclonal antibodies having specific reactivity with adenosine triphosphate binding domains, caspase recruitment domains and triosephosphate isomerase domain peptides, used for modulation of apoptosis
12/16/2004	US20040253226 administering to the animals angiogenesis inhibitors comprising kallikreins such as prostate specific antigens (PSA), hydrolase enzymes homologs or fragments; prophylaxis of cancer, arthritis and vision defects
12/16/2004	US20040253182 Pathological tissue detection and treatment employing targeted benzoindole optical agents
12/16/2004	US20040253181 Novel compositions magnetic particles covered with gem-bisphosphonate derivatives
12/16/2004	DE10324282A1 Kombination von Acetylsalicylsäure und Alpha-Glucosidase-Inhibitoren Combination of acetylsalicylic acid and alpha-glucosidase inhibitors
12/16/2004	CA2528164A1 Solid preparation
12/16/2004	CA2527779A1 3-substituted indoles and derivatives thereof as therapeutic agents
12/16/2004	CA2526792A1 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
12/16/2004	CA2526694A1 Amidino compounds as cysteine protease inhibitors
12/15/2004	EP1486508A1 Use of the AL-1 neurotrophic factor, a ligand for an EPH-related tyrosine kinase receptor, for the preparation of a medicament for modulating angiogenesis associated disease or condition
12/15/2004	EP1486507A1 Transmembrane nfat inhibitory peptide
12/15/2004	EP1486505A1 Angiotensin derivatives
12/15/2004	EP1486501A1 Aminomethyl-substituted thiazolobenzimidazole derivative
12/15/2004	EP1486497A1 Novel pyridone derivative
12/15/2004	EP1486496A1 Substituted 2-(2,6-Dioxopiperidin-3-YP)-Phthalimides and 1-Oxoisoindolines and method fo reducing TNF alpha levels
12/15/2004	EP1486494A1 N-substituted benzothiophenesulfonamide derivative
12/15/2004	EP1486491A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
12/15/2004	EP1486487A1 Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate
12/15/2004	EP1486214A1 Botulinum toxins for treating muscle spasm
12/15/2004	EP1485476A2 Dimeric tf antagonist
12/15/2004	EP1485388A2 Topiramate salts and compositions comprising and methods of making and using the same
12/15/2004	EP1485386A2 Pyridinyloxy derivatives as 5-ht receptor ligands
12/15/2004	EP1485384A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
12/15/2004	EP1485381A1 Azolylaminoazine as inhibitors of protein kinases
12/15/2004	EP1485380A1 Azolylaminoazines as inhibitors of protein kinases
12/15/2004	EP1485379A1 Beta 3-adrenergic receptor agonists
12/15/2004	EP1485377A1 Pyranones useful as atm inhibitors
12/15/2004	EP1485375A1 Pyrimidine compounds
12/15/2004	EP1485374A1 Pyrimidine compounds
12/15/2004	EP1485371A2 Indole amide derivatives and their use as glycogen phosphorylase inhibitors
12/15/2004	EP1485370A1 Amino-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485368A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
12/15/2004	EP1485364A1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485363A1 Cyclic amides
12/15/2004	EP1485359A2 Sodium channel blockers
12/15/2004	EP1485354A1 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485353A1 New inhibitors of histone deacetylase
12/15/2004	EP1485347A2 Hif hydroxylase inhibitors
12/15/2004	EP1485132A2 Combination of an aldosterone receptor antagonist and a fibric acid derivative
12/15/2004	EP1485121A2 Activated protein c formulations
12/15/2004	EP1485109A1 Vascular therapeutics
12/15/2004	EP1485108A2 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
12/15/2004	EP1485105A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
12/15/2004	EP1485104A1 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
12/15/2004	EP1485100A1 Azinylaminoazoles as inhibitors of protein kinases
12/15/2004	EP1485099A1 Inhibitors of histone deacetylase
12/15/2004	EP1485096A2 Methods for preventing or treating cardiac arrhythmia
12/15/2004	EP1485095A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
12/15/2004	EP1485092A1 Use of rapamycin for inhibiting of cell death
12/15/2004	EP1485091A1 Thiazole and oxazole derivatives that modulate ppar activity
12/15/2004	EP1485089A1 Combination treatments for chemokine-mediated diseases
12/15/2004	EP1485088A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
12/15/2004	EP1485086A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
12/15/2004	EP1485085A1 Phosphate prodrugs of fluorooxindoles
12/15/2004	EP1485083A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
12/15/2004	EP1485080A1 Use of adapalene for the treatment of dermatological disorders
12/15/2004	EP1485078A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
12/15/2004	EP1414470A4 Micronutrient phosphates as dietary and health supplements
12/15/2004	EP1401862A4 Peptide compounds for counteracting reactive oxygen species and free radicals
12/15/2004	EP1399155A4 Small molecules useful in the treatment of inflammatory disease
12/15/2004	EP1387840B1 3,5-diamino-1,2,4-triazoles as kinase inhibitors
12/15/2004	EP1373216B1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
12/15/2004	EP1368303B1 Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases
12/15/2004	EP1322300B1 Inhalation particles incorporating a combination of two or more active ingredients
12/15/2004	EP1309594B1 Benzimidazole derivatives, preparation and therapeutic use thereof
12/15/2004	EP1307447B1 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
12/15/2004	EP1301517B1 Thienopyrrolidinones
12/15/2004	EP1259248B1 Methods for treating cancers expressing vascular endothelial growth factor d
12/15/2004	EP1249245B1 Remedies and/or preventives for nervous system disorders
12/15/2004	EP1226160B1 Novel antiarrhythmic peptides
12/15/2004	EP1226137B8 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
12/15/2004	EP1218005B1 Vitronectin receptor antagonists
12/15/2004	EP1149063B1 Ureido-thiobutyric acid derivatives as ppar-agonists
12/15/2004	EP1119543B1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
12/15/2004	EP1068180B1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors

1 ... 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 ... 1595